Navigation Links
For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
Date:12/8/2010

BURLINGTON, Mass., Dec. 8, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

The Pharmacor 2010 findings from the topic entitled Ovarian Cancer which will publish later this month reveal that, since the publication of data last year from the CALYPSO clinical trial, PLD (Centocor Ortho Biotech/Janssen's Doxil, Merck's Caelyx) is being increasingly used in combination with carboplatin (Bristol-Myers Squibb's Paraplatin, generics) as an alternative to paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin in the second-line, platinum-sensitive population. As a result, Decision Resources forecasts that PLD/carboplatin will replace paclitaxel/carboplatin by 2019 as the gold-standard treatment in this setting in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

According to the findings, urgent unmet need remains for therapies that can delay or prevent progression to platinum-resistant ovarian cancer.

"Experts we interviewed believe that such gains in addressing unmet need will most likely come from novel targeted agents," said Decision Resources Analyst Niamh Murphy, Ph.D. "As such, the need exists to identify other genetic characteristics -- in addition to BRCA1/BRCA2 mutations -- that will lead to the development of novel, molecularly targeted drugs which will benefit patients with ovarian cancer."

The findings also reveal that dramatic growth in the ovarian cancer drug market through 2019 will be driven primarily by the approval and uptake of four premium priced targeted ther
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014   Auxilium Pharmaceuticals , Inc. ... biopharmaceutical company, today announced that the Company will release ... August 7, 2014 before the opening of the U.S. ... call that day at 8:30 a.m. ET to discuss ... The presentation slides to be used during the call ...
(Date:7/31/2014)... , July 31, 2014  A substantial share ... decisions about which therapies are included in formularies—say ... according to a new Manhattan Research study, ... The study finds that P&T committee members in ... managers (PBMs) have set a high bar for ...
(Date:7/31/2014)... Catylix, Inc. ( Burbank, California ... California ) announced today the formation of ... fluorination products and related chemistry. Developing ... use of substituents that are chemically stable, resistant ... improve binding and bioavailability. Fluorinated functional groups are ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... FDA Clearance for a Phase II Trial of Its Long-Acting... -- NES-ZIONA, Israel, Aug. 24 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... CHICAGO, Aug. 24 Advanced Life Sciences Holdings, ... a biopharmaceutical company engaged in the discovery, development and ... infection, oncology and respiratory diseases, today announced plans to ... once-daily antibiotic, Restanza™ (cethromycin) based on a new, high-profile ...
Cached Medicine Technology:PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 2PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 3PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 4PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 5PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 6PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 7PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 8Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report 2Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report 3Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report 4Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report 5
(Date:7/31/2014)... July 31, 2014 The Alaska ... hiring of new dentist Dr. Jonathan Oudin, DDS, who ... previously practiced in Barrow, Alaska, for three years. According ... Dentistry hired Dr. Oudin to help take on new ... Dentistry to continue growing and serving the greater Anchorage ...
(Date:7/31/2014)... THURSDAY, July 31, 2014 (HealthDay News) -- With the ... the West African Ebola outbreak has risen to 729, ... on Thursday issued a travel warning for,the region. ... travel to the affected countries -- Guinea, Liberia and ... is that Ebola is worsening in West Africa," CDC ...
(Date:7/31/2014)... Scientists have learned that recent fears of invasive lionfish ... efforts to control lionfish by fishing derbies and targeted ... invasion. And there,s a simple way to know for ... after it,s been cooked. , Pacific lionfish were first ... and have been gaining swiftly in number ever since. ...
(Date:7/31/2014)... 31, 2014 Insight Accelerator Labs member ... A round of investment for $4.6 million to fund ... collecting vital signs. The company joined Insight Accelerator ... fruition with the help of Insight development teams. ... for launching the Accelerator,” says Steve McPhilliamy, Executive Director ...
(Date:7/31/2014)... FL (PRWEB) July 31, 2014 Women ... to take charge of their financial future. The ... women, has opened registration for 6 upcoming Los Angeles ... women, for women, and with input from Kim Kiyosaki, ... and It’s Rising Time) who is passionate about women’s ...
Breaking Medicine News(10 mins):Health News:Dr. Jonathan Oudin to Join Alaska Center for Dentistry at Wasilla Location 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Insight Accelerator Labs Advances Member Toward Commercialization 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2
... 31 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE:,MDZ), ... the global life,sciences markets, announced today that Stephen ... presenting at the Thomas Weisel Partners,Healthcare Conference in ... Standard Time. Interested parties may access the ...
... 31 Mylan Laboratories Inc.,(NYSE: MYL ) ("Mylan") ... for cash any and all of its outstanding 5.750% ... Notes due 2015 (CUSIP Nos.,628530AF4, 628530AC1) (collectively, the "Notes"). ... of a broader strategy to,establish its new global capital ...
... - QLT USA, Inc., a subsidiary,of QLT Inc. ... that the European,approval procedure for the Eligard(R) 45 ... formulation in 23 European countries,is expected to follow ... the individual countries. The 6-month formulation was launched ...
... UHW-West and 121RN, their, first ever wage scales ... Calif., Aug. 30 Caregivers at Providence St.,Joseph Medical ... -,West (UHW) and SEIU 121RN, reached a tentative agreement ... contract, which expires,Sept. 30, 2011, grants workers their first ...
... are likely culprits behind the increase, , , THURSDAY, Aug. ... in one sport early -- playing year-round, joining competitive ... programs -- believing they,ll put themselves on the fast ... sports career. , But for too many of these ...
... Over Health & Safety of,Seniors in Nursing Homes, ... death linked to an untreated oral infection, the,statewide organization ... oral health of seniors residing in nursing and,convalescent homes., ... it can be a matter of life and,death, especially ...
Cached Medicine News:Health News:Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Merck's Generic Pharmaceutical Business 2Health News:Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Merck's Generic Pharmaceutical Business 3Health News:Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Merck's Generic Pharmaceutical Business 4Health News:Eligard(R) six-month formulation successfully completes European approval procedure 2Health News:Eligard(R) six-month formulation successfully completes European approval procedure 3Health News:Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract 2Health News:More Kids Are Suffering Sports Injuries 2Health News:More Kids Are Suffering Sports Injuries 3Health News:Oral Health a Matter of Life and Death for Seniors 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: